CO-OPTIV-SECURITY
30.5.2019 17:07:07 CEST | Business Wire | Press release
Optiv Security, a global cybersecurity integrator delivering end-to-end cybersecurity solutions, has been recognized with the second highest score in the current offering category for cybersecurity incident response services by Forrester Research. The Forrester WaveTM : Cybersecurity Incident Response Services, Q1 2019 identifies Optiv as having received the highest possible score for the criteria of incident preparation, post-incident reporting and support, and average hours per response.
The report cites that “Optiv … has an excellent current offering,” noting that “it has a well-stated engagement model, and its postmortem deliverables include remediation road maps to help clients avoid repeat occurrences, and its client references were positive across the board.” The report also states that “Optiv would be a good choice from incident preparation through remediation.”
“Today’s business decision makers are faced with driving technology, product, and business growth, while being simultaneously tasked with maintaining cyber resilient programs that are ready to react, respond to, and recover from adverse events,” said Bill Young, Optiv’s vice president and general manager of advisory threat management. “Achieving cyber resiliency requires a strategy that leverages security best practices, including proactive incident management planning, programmatic penetration testing, effective detection and response capabilities, and real-time tailored threat intelligence. By addressing enterprise cybersecurity needs from the perspective of the enemy, organizations can create more successful cyber resilient programs that are built on factual-based offensive security testing.”
Young continued, “Optiv is in a unique position in the industry to provide clients with unmatched insight, depth and breadth of services, as well as a bench that extends throughout the complete ‘plan, build, run’ cybersecurity lifecycle. We are focused on enabling our clients to move from putting out fires to preventing threat actor actions and enabling their businesses. We do this by helping organizations create, prepare, and execute incident response strategies that are honed and practiced as their organizations change, providing skilled and experienced resources to augment internal staff, and delivering supporting services, such as threat hunting and forensics capabilities that help reduce breach levels and data loss. We believe receiving the second highest score in the current offering category from Forrester validates our unique approach and the positive impact we have on our clients’ operations.”
Optiv’s enterprise incident management services help organizations reduce the likelihood of attacks or incidents, secure their environments against threats, and recover from incidents while minimizing disruption. Optiv’s full suite of EIM services can be purchased in structures aligned to the clients’ business model, thereby enabling organizations to:
- Prepare – identify gaps in incident management strategy, hunt for and detect unknown threats within their infrastructure, document key personnel and escalation steps, validate and test response efforts for incidents and identify next steps to become more resilient.
- Respond During and Post Incident – uncover attackers’ actions, detail the scope of a compromise, identify steps to remove active threats found in their environments, limit data loss, and improve security controls.
- Maintain – ensure they are in a continual state of readiness for unexpected attacks or incidents with Optiv experts who are on-call and available 24x7x365. Optiv’s security and malware professionals examine clients’ systems for indicators of compromise, conduct analysis informed by a vast proprietary knowledge store of malicious code, signatures and attacks, and provide ongoing expertise.
Please visit Optiv’s website to learn more about Optiv’s incident management services .
Follow Optiv
Twitter: www.twitter.com/optiv
LinkedIn:
www.linkedin.com/company/optiv-inc
Facebook:
www.facebook.com/optivinc
YouTube:
https://www.youtube.com/c/OptivInc
Blog:
www.optiv.com/explore-optiv-insights/blog
About Optiv Security
Optiv is a global cybersecurity
solutions integrator – a “one-stop” trusted partner with a singular
focus on cybersecurity. Our end-to-end cybersecurity capabilities span
risk management and transformation, cyber digital transformation, threat
management, cyber operations, identity and data management, and
integration and innovation, helping organizations realize stronger,
simpler and more cost-efficient cybersecurity programs that support
business requirements and outcomes. At Optiv, we are modernizing
cybersecurity to enable clients to innovate their consumption models,
integrate infrastructure and technology to maximize value, achieve
measurable outcomes, and realize complete solutions and business
alignment. For more information about Optiv, please visit us at www.optiv.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190530005565/en/
Contact:
Jason Cook (816) 701-3374 Jason.cook@optiv.com or Brett Ater (913) 304-7683 Brett.ater@optiv.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
